Related Experiment Video
Updated: Feb 16, 2026
10:39
Qualitative and Quantitative Validation of Tools with Rating Scales Aimed at Assessing the Quality of University Service-Learning
Published on: August 29, 2025
1.2K
Comparing and transforming PROMIS utility values to the EQ-5D
John D Hartman1, Benjamin M Craig2
1Department of Health Sciences and Administration, University of West Florida, Pensacola, FL, USA. jhartman@uwf.edu.
Summary
This study compares Patient Reported Outcomes Measurement Information System (PROMIS-29) and EQ-5D-3L health utility values. Mapping PROMIS-29 values to the EQ-5D-3L scale allows for better comparisons between health instruments.
Area of Science:
- Health Economics
- Psychometrics
- Biostatistics
Background:
- Patient-reported outcomes (PROs) are crucial for economic evaluations of medical treatments.
- Quality-adjusted life year (QALY) scales are used to summarize PROs.
- Comparing different PRO instruments is essential for accurate economic modeling.
Purpose of the Study:
- To compare the preference-based summary of EQ-5D-3L and PROMIS-29 instruments.
- To transform PROMIS-29 utility values to an EQ-5D-3L scale for direct comparison.
Main Methods:
- A national survey of 2623 US adults completed both PROMIS-29 and EQ-5D-3L instruments.
- Utility weights were calculated using published estimates for both instruments.
- Regression analysis compared PROMIS-29 and EQ-5D-3L utility weights against each other and self-reported general health.
Main Results:
- PROMIS-29 utility weights were substantially lower than EQ-5D-3L weights.
- A strong correlation (0.769) indicates the difference is primarily a scale disparity.
- A formula was derived to map PROMIS-29 utility values onto the EQ-5D-3L scale: EQ-5D-3L losses = 0.1784 × (PROMIS-29 Losses)^0.7286.
Conclusions:
- Published PROMIS-29 estimates yield lower utility values compared to other health instruments.
- Mapping PROMIS-29 utility values to the EQ-5D-3L scale resolves this discrepancy.
- This mapping facilitates more direct and meaningful comparisons between PROMIS-29 and other common health instruments in economic evaluations.
Related Concept Videos
01:16Bioequivalence Data: Statistical Interpretation
236
Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
236
01:16Bioequivalence: Overview
2.0K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.0K
01:22Dose-Response Relationship: Potency and Efficacy
6.7K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.7K
01:26Pharmaceutical Equivalents
209
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
209
01:26Social Exchange Theory
525
As formulated by John Thibaut and Harold Kelley, Social Exchange Theory explains human relationships as economic-like exchanges that maximize rewards and minimize costs. This theory suggests that individuals engage in relationships to gain benefits and reduce burdens, similar to economic transactions. It has been widely applied to various types of relationships, including romantic, professional, and social interactions.Rewards and Costs in RelationshipsRelationship rewards include emotional...
525
01:17Equivalence: In Vitro and In Vivo Bioequivalence
256
Body:Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts.
256